Tekla Capital Management’s Coherus Oncology CHRS Stock Holding History

Tekla Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-203,103	Closed	-$3.73M	–	206
2020 Q3	$3.73M	Hold	203,103	–	–	0.14%	118
2020 Q2	$3.63M	Buy	203,103 +91,440	+82%	+$1.55M	0.14%	124
2020 Q1	$1.81M	Sell	111,663 -13,483	-11%	-$249K	0.08%	139
2019 Q4	$2.25M	Sell	125,146 -70,000	-36%	-$1.29M	0.09%	147
2019 Q3	$3.95M	Sell	195,146 -96,273	-33%	-$1.92M	0.17%	97
2019 Q2	$6.44M	Sell	291,419 -23,743	-8%	-$412K	0.26%	80
2019 Q1	$4.3M	Hold	315,162	–	–	0.17%	101
2018 Q4	$2.85M	Buy	315,162 +165,342	+110%	+$1.91M	0.12%	111
2018 Q3	$2.47M	Sell	149,820 -91,023	-38%	-$1.61M	0.09%	134
2018 Q2	$3.37M	Buy	240,843 +59,820	+33%	+$856K	0.13%	110
2018 Q1	$2M	Buy	181,023 +91,023	+101%	+$996K	0.08%	135
2017 Q4	$792K	Hold	90,000	–	–	0.03%	148
2017 Q3	$1.2M	Hold	90,000	–	–	0.04%	134
2017 Q2	$1.29M	Hold	90,000	–	–	0.05%	127
2017 Q1	$1.9M	Hold	90,000	–	–	0.07%	114
2016 Q4	$2.53M	Buy	+90,000	New	+$2.52M	0.11%	96

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Tekla Capital Management's CHRS Position: Q4 2020 in Review

Tekla Capital Management sold out of Coherus Oncology (CHRS) in Q4 2020, closing a stake of 203,103 shares — an estimated $3.73M sold.

Tekla Capital Management first reported a position in CHRS in Q4 2016 and held it in 16 quarters. The position peaked at $6.44M in Q2 2019. 196 funds tracked by Wall St. Rank hold CHRS as of Q4 2020.

Tekla Capital Management reported no remaining Coherus Oncology position as of Q4 2020 after selling out during the quarter.
Tekla Capital Management sold 203,103 Coherus Oncology shares in Q4 2020, an estimated $3.73M.
Tekla Capital Management first reported a position in Coherus Oncology in Q4 2016 and held it in 16 quarters.
Tekla Capital Management's Coherus Oncology position peaked at $6.44M in Q2 2019.
196 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2020.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.